14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IOVA vs BIIB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IOVA carries a Unified Composite Score of 70.4/100 (BUY) at $7.63 (N/M Forward P/E, -60.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin).
Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (70.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. -60.8% operating margin) and revenue trajectory (+10.6% vs. +80.1% YoY).
Technical & Structure Timing Caution: IOVA is currently in a Breakdown options structure phase (RSI 32.5); meanwhile BIIB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment52.3% of Rev ($5.39B)
90D Engineering Disclosures0 Published
Investor FAQ IOVA vs BIIB Key Questions & Quantitative Answers
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IOVA carries a Unified Composite Score of 70.4/100 (BUY) at $7.63 (N/M Forward P/E, -60.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin). Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (70.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. -60.8% operating margin) and revenue trajectory (+10.6% vs. +80.1% YoY). Technical & Structure Timing Caution: IOVA is currently in a Breakdown options structure phase (RSI 32.5); meanwhile BIIB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IOVA leads the Growth & Scale pillar: IOVA posts +80.1% YoY revenue growth and +0.0% YoY earnings growth on $379M TTM revenue (53.2% gross margin, -60.8% operating margin), compared with BIIB at +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IOVA cumulative revenue shifted +62.5% while BIIB shifted -26.5%. In operating R&D and SG&A reinvestment, IOVA deploys N/A (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($5.39B) (0 disclosures) for BIIB.
BIIB screens cheaper on headline valuation multiples. IOVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.3x EV/Revenue (-57.0% FCF margin), whereas BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IOVA (-29.1% ROE) versus BIIB (1.9% ROE) capital efficiency.
In options market volatility and institutional positioning, IOVA carries 83.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 144% Vol realized risk). By comparison, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.